Board approved preferential issuance of 11,70,000 equity shares to non-promoters and 20,00,000 convertible warrants to promoters and promoter group at Rs 10 per security; warrants are exercisable within 18 months. The equity issue represents 10.11% post-issue shareholding, while promoter-group holdings could rise to 30.03% fully diluted from 19.96%. Board also approved divestment of two subsidiaries to director Vijaya Lakshmi Boda. The subsidiary sale is a related-party transaction: 51.43% of Life 108 Healthcare was transferred for Rs 18.0 lakh and 99% of Beastbells Media for Rs 0.2 lakh; Life 108 contributed 44.90% of FY25 income. Valuation rationale and strategic impact were not disclosed.